| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| Neurology supplements are not peer-reviewed. Information contained in Neurology supplements represent the opinions of the authors and are not endorsed by nor do they reflect the views of the American Academy of Neurology, Editor-in-Chief, or Associate Editors of Neurology. |
From the Department of Neuroscience, University of Pisa (U.B.) and Neurology Unit, Hospital of Viareggio (P.D.D.), Pisa, Italy.
Address correspondence and reprint requests to Dr. Ubaldo Bonuccelli, Universita’ Di Pisa, Dip. di Neuroscienze, Via Roma 55, Pisa, Italy; e-mail: u.bonuccelli{at}med.unipi.it
Many of the motoric features that define Parkinson’s disease (PD) result primarily from the loss of dopaminergic neurons of the substantia nigra. l-dopa remains at present the most powerful symptomatic drug for the treatment of this condition. However, motor complications of chronic l-dopa treatment have emerged as a major limitation of this therapy. Slowing or delaying the progression of the disease with neuroprotective therapies may delay the need for l-dopa. In the past few years, novel insight into the pathogenetic mechanisms of neurodegeneration in PD has been provided. Mitochondrial function deficiency, increased oxidative stress, apoptosis, excitotoxicity, and inflammation are part of the processes that ultimately result in neurodegeneration. Drugs that are now under clinical scrutiny as neuroprotectant include molecules that combine one or more of the following properties: (1) monoamine oxidase inhibition (rasagiline, safinamide); (2) mitochondrial enhancement (coenzyme Q10, creatine); (3) antiapoptotic activity; (4) anti-inflammatory activity; (5) protein aggregation inhibition; (6) neurotrophic activity. In advanced Parkinson’s disease, the combination of disease progression and l-dopa therapy leads to the development of motor response complications, particularly wearing off, on off, dyskinesias and dystonias. The nonphysiologic pulsatile stimulation of striatal dopamine receptors, produced by the currently available dopaminergic drugs, may trigger a dysregulation of many neurotransmitter systems within the basal ganglia, mainly localized on medium spiny striatal neurons. These include alterations of glutamatergic, serotonergic, adrenergic and adenosine A2A receptors. Novel strategies for pharmacological intervention with nondopaminergic treatments hold the promise of providing effective control or reversal of motor response complications. Of particular interest are NMDA and AMPA antagonists or drugs acting on 5-HT subtype 2A, alpha2-adrenergic, and adenosine A2 receptors. Future strategies may also target pre- and postsynaptic components that regulate firing pattern of basal ganglia neurons, such as synaptic vesicle proteins, nonsynaptic gap junction communication mechanisms, or signal transduction systems that modulate the phosphorylation state of glutamatergic receptors.
Publication of this supplement was supported by a grant from Newron Pharmaceuticals.
Disclosure: The authors report no conflicts of interest.
Neurology supplements are not peer-reviewed. Information contained in Neurology supplements represents the opinions of the authors and is not endorsed by nor does it reflect the views of the American Academy of Neurology, Editorial Board, Editor-in-Chief, or Associate Editors of Neurology.
This article has been cited by other articles:
|
|
 |
|
  C. Xiao, R. Nashmi, S. McKinney, H. Cai, J. M. McIntosh, and H. A. Lester Chronic Nicotine Selectively Enhances {alpha}4{beta}2* Nicotinic Acetylcholine Receptors in the Nigrostriatal Dopamine Pathway J. Neurosci., October 7, 2009; 29(40): 12428 - 12439. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Rav-Acha, H. Bergman, and Y. Yarom Pre- and Postsynaptic Serotoninergic Excitation of Globus Pallidus Neurons J Neurophysiol, August 1, 2008; 100(2): 1053 - 1066. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Hashimoto and H. Kita Serotonin Activates Presynaptic and Postsynaptic Receptors in Rat Globus Pallidus J Neurophysiol, April 1, 2008; 99(4): 1723 - 1732. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. B. Yim, S. E. Park, and C. S. Lee Protective Effect of Glycyrrhizin on 1-Methyl-4-phenylpyridinium-Induced Mitochondrial Damage and Cell Death in Differentiated PC12 Cells J. Pharmacol. Exp. Ther., May 1, 2007; 321(2): 816 - 822. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
